Certified by Founder
Lodge
Umoja Biopharma
start up
United States
- Seattle, Washington
- 21/01/2025
- Series C
- $100,000,000
Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies
- Industry Biotechnology Research
- Website https://www.umoja-biopharma.com/
- LinkedIn https://www.linkedin.com/company/umoja-biopharma/
Related People
Andy ScharenbergFounder
United States -
Seattle, Washington
Physician, Scientist, Entrepreneur, passionate about the impact that CAR T-cells can have on the treatment of cancer.
Integrate | $17,000,000 | (Feb 13, 2026)
daypass.com | $2,000,000 | (Feb 13, 2026)
CYDELPHI | $3,000,000 | (Feb 13, 2026)
Maestro Tech, Inc. | $1,200,000 | (Feb 13, 2026)
Ever | $31,000,000 | (Feb 13, 2026)
Manufact (formerly mcp-use) | $6,300,000 | (Feb 13, 2026)
Reflow | $15,000,000 | (Feb 13, 2026)
Santé(US) | $7,600,000 | (Feb 13, 2026)
Alva Energy | $33,000,000 | (Feb 13, 2026)
Project Omega | $12,000,000 | (Feb 13, 2026)
Brandlight | $30,000,000 | (Feb 12, 2026)
Inertia | $450,000,000 | (Feb 12, 2026)